The role of liver transplantation in 29 patients with fulminant and subacute hepatic failure due to a variety of different causes was examined by comparing the outcome and a variety of "hospitalization" variables. Transplanted patients (n = 13) were more likely to survive (p < 0.05), were younger (p < 0.05) and spent more time in the hospital (p < 0.025) than did those who were not transplanted (n = 16). Despite spending a much longer time in the hospital, transplaRted patients spent less time in the intensive care unit (p < 0.05) in coma (p < 0.01) and on a respirator (p < 0.01) than did ~hose not transplanted. Most importantly, the survival rate for transplanted patients was significantly improved (p < 0.05) as compared to those not transplanted. We conclude that liver transplantation can be applied successfully to the difficult clinical problem of fulminant and subacute hepatic failure.
MATERIALS AND METHODS
Definitions. For the purpose of this study, fulminant bepatic failure was defined as the occurrence of severe impairment of hepatocellular function progressing to advanced encephalop. athy (either advanced Stage 3 or Stage 4) within 8 weeks of onset-in an individual without a history or not of evidence of previous hepatic disease. Subacute hepatic failure was defined as the occurrence of severe irreversible liver failure which developed within 8 to 28 weeks from the onset of symptoms in an individual without an antecedent. history or evidence of chronic liver disease.
Patients. All patients admitted to either the medical or surgical services of the authors of this paper with a diagnosis of acute fulminant or subacute hepatic failure in advanced Stage III or Stage IV coma have been considered as possible candidates for OLTx since February, 1981 . Since that time and until July 1, 1985, a total of 29 patients have been evaluated with these two diagnoses. Of these 29, 11 had fulminant viral hepatitis documented by the appropriate viral serologic studies and/or a clinical history of a needle stick or other blood exposure in the cases of non-A, non-B fulminant hepatitis. Nine patients had subacute Wilson's disease documented by the presence of Kayser Fleischer rings, an increased urine and hepatic content of copper and a reduced serum ceruloplasmin level. Nine patients were thought to have fulminant drug or toxin-induced hepatotoxicity based upon a clinical history of recent drug or toxin exposure, a consistent history of fever and rapid onset of hepatotoxicity associated in most cases with an eosinophilia and the absence of any serologic or other laboratory data to suggest an alternative diagnosis of a recognizable viral or metabolic liver disease. Diagnostic Evaluation of the Patients. Each patient underwent a complete liver transplant evaluation consisting of the studies required to identify the specific etiology and the severity of their disease, and to recognize and manage any complications that may have developed. This evaluation hal been described before and has not changed over the 41h years which encompass this report (16) (17) (18) . Chart Review and Validation. The charts of the 29 patients included in this study were reviewed following ~~~ discharge or death to obtain the various data herein repo~ All records including intensive care unit data sheets, anestbeIIA records, operative reports and the medical and surgical progress notes were reviewed. In addition, the health status of the 10 surviving patients has been determined by telephone cont.ad. with the patients and their local physicians. OLTx FOR FULMINANT HEPATIC FAILURE o~ Tx has been considered to be antecedent to the outcome I;urvival), and thus the odds ratio has been used to measure (he odds in favor of experiencing the outcome (survival). When (he confidence interval around the odds ratio excluded unity, indicating excess odds in favor, the significance of the associ-.tion between transplantation and survival was tested using X 2 119, :W).
RESULTS
The mean age of the 29 patients included in this study ~'as 27.5 ± 2.2 years. Sixteen were female and 13 were male. Table 1 shows the individual ages, final diagnoses,' t"pe of hepatic failure, time from admission to onset of roma and outcome of the 29 patients studied. Table 2 show~ the liver injury and hematologic parameters of the patients studied just before OLTx or at the time of death or peak level of abnormality (which ever was greater) if OL Tx was not performed.
Of In order to determine whether any differences existed between those who died waiting to be transplanted and those who actually lived long enough to receive a transplant, the age, the time spent in hospital, time spent in an intensive care unit, and the time in coma and/or on a respirator either prior to transplantation or death as well as the amount of blood products consumed by these patients were compared (Tables 3 to 5 ). The patients who lived long enough to be transplanted following admission to the hospital were younger (p < 0.05) and spent less time in the intensive care unit (p < 0.05), in coma (p < 0.01) and on a respirator (p < 0.01) than did those who died waiting to be transplanted (Tables 3 and 4 ). However, because the patients who were transplanted survived the early hospital period, as a result of being tr8!.!Planted, they spent more total time in the .hospital than did those who were not transplanted, most of whom (13 of 16 or 81 %) died (Table 3 ). Despite such a greater hospitalization time for those transplanted compared to those not transplanted, no significant difference for blood product consumption was evident between the four groups.
In order to determine what factors contributed to a poor posttransplant outcome, the same variables as well as several others known to affect survival following OL Tx were compared between those who survived and those who did not survive OLTx (Table 4) . No statistical differences between the two groups were evident for any of the 16 separate variables studied. However, a trend for a greater amount of time spent in the intensive care unit, time on a respirator and units of blood products consumed prior to transplantation was seen for the nonsurviving group. Had the two groups been larger, these differeaces may have achieved statistical significance. It should be noted, however, that the survivors had a longer hospitalization prior to transplant than did those who died, suggesting that they may have been less severely ill initially. Again, Table 5 . Figure 2 shows a life table analysis of the 29 patients berein reported. The survival rates at time points of 1 lIlonth or longer from time of hospital admission were significantly increased in the transplanted group as compared to those who did not receive a transplant. Specifically. he odds in favor of survival (odds rati?; upper 95% cunfidence interval; lower 95% confidence mterval; and X ~ significance level, respectively) as a result of OLTx were increased 7-fold at 1 month (7.33 
DISCUSSION
This report clearly documents the poor prognosis of patients with acute fulminant and subacute hepatic failure v'ether treated medically or surgically. It also supports ,he commonly held idea that youthful persons do better than do older patients with such an ·illness. It should be noted, however, that only 4 of our 29 subjects were less than, 20 years of age, the usual cut-off age cited for individuals having a better prognosis with fulminant or subacute hepatic failure. Moreover, two of these four died while one recovered without OLTx ( Table 1) . Thus, we do not believe that the younger mean age of the transplanted patients accounts for their greater survival. Most importantly, this report demonstrates that the shofter the time the patient is in coma and/or on a respirator, the better the overall prognosis of the patient. This observation is consistent with earlier reports of poorer posttransplant survival in patients hospitalized within intensive care units and those on respirators prior to OLTx (21). Finally, the present data document that liver transplantation alters the natural history of patients in advanced Stage III or IV hepatic coma due to acute fulminant and subacute hepatic failure by improving survival and changir.g the causes of death in those who ultimately die. Specifically, those who die prior to transplantation do so because of hepatic failure or one of it's several associated complications (Table 5) , while those who die after transplantation do so primarily because of either bacterial or fungal sepsis or renal failure, both of which are probably related to the use of cyclosporin-prednisone immunosuppression. The causes of death following transplantation observed in the patients herein reported do not differ from those of patients transplanted for the more usual indications for OL Tx reported previously (22) . Nonetheless, the present data clearly document a 2.8-fold increased survival rate at 6 months for those patients who were transplanted as compared to those who were not. Data concerning the long-term survival of these patients are currently not available. However, as one would not expect the original toxic or metabolic liver disease to reoccur in the patients with such diseases originally, it is not unreasonable to believe that their long-term survival should be no different from that of individuals surviving OL Tx performed for other indications. These data suggest that the survival curve is nearly flat 3 months after OLTx and remains so for approximately 6 years, the limits provided by the currently available experience for the large number of patients surviving OLTx. It is of some interest to note moreover that the single survivor of acute fulminant type B hepatitis became hepatitis B surface antibody-positive postoperatively and is currently working full time free of any clinical or biochemical evidence of liver disease. Finally, it should be noted that liver failure, particularly its fulminant and subacute hepatic forms, is not a homogenous condition and that survival is known to be influenced by the underlying etiology (23, 24) . In fact, the mix of patients herein reported is somewhat unusual, with 9 of the 29 having had fulminant Wilson's disease. It should be noted in addition, however, that with the exception of this report, no case of fulminant Wilson's disease has been reported to survive to date without OLTx. It should also be noted that only those who use less restrictive definitions of fulminant and subacute hepatic failure (e.g., not requiring the obligate presence of deep Stage 3 or Stage 4 coma) have reported survival rates of between 33 and 70%, which are comparable to what we have found in advanced stages of hepatic encephalopathy (1, 3, 5, 10, (23) (24) (25) (26) (27) (28) . Clearly, the role of liver transplantation in patients having less severe fulminant or subacute hepatic dysfunction but not in advanced Grade 3 or 4 hepatic encephalopathy but rather in Stage 2 and early Stage 3 remains to be determined. The current data suggest, however, that once an advanced stage of hepatic encephalopathy is reached, that liver transplantation improves survival in this particularly ill subset of patients with fulminant and subacute hepatic failure. This is particularly evident when one considers that spontaneous recovery, as evidenced by a return of consciousness, removed patients herein reported from the active transplant candidate list and thereby actually prejudices the data for survival in favor of the group not transplanted.
